0001213900-24-069245.txt : 20240814 0001213900-24-069245.hdr.sgml : 20240814 20240814182524 ACCESSION NUMBER: 0001213900-24-069245 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20240812 FILED AS OF DATE: 20240814 DATE AS OF CHANGE: 20240814 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Citius Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001506251 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences STATE OF INCORPORATION: NV FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-41534 FILM NUMBER: 241210027 BUSINESS ADDRESS: STREET 1: 11 COMMERCE DRIVE STREET 2: 1ST FLOOR CITY: CRANFORD STATE: NJ ZIP: 07016 BUSINESS PHONE: (908) 967-6676 MAIL ADDRESS: STREET 1: 11 COMMERCE DRIVE STREET 2: 1ST FLOOR CITY: CRANFORD STATE: NJ ZIP: 07016 FORMER NAME: FORMER CONFORMED NAME: Trail One, Inc. DATE OF NAME CHANGE: 20110314 FORMER NAME: FORMER CONFORMED NAME: TrailOne, Inc. DATE OF NAME CHANGE: 20101119 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: CITIUS ONCOLOGY, INC. CENTRAL INDEX KEY: 0001851484 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: E9 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 420 LEXINGTON AVE, STREET 2: SUITE 2446 CITY: NEW YORK STATE: NY ZIP: 10017 BUSINESS PHONE: (347) 627-0058 MAIL ADDRESS: STREET 1: 420 LEXINGTON AVE, STREET 2: SUITE 2446 CITY: NEW YORK STATE: NY ZIP: 10017 FORMER COMPANY: FORMER CONFORMED NAME: TenX Keane Acquisition DATE OF NAME CHANGE: 20210315 4 1 ownership.xml X0508 4 2024-08-12 0 0001851484 CITIUS ONCOLOGY, INC. CTOR 0001506251 Citius Pharmaceuticals, Inc. C/O CITIUS ONCOLOGY, INC. 11 COMMERCE DRIVE, 1ST FLOOR CRANFORD NJ 07016 0 0 1 0 0 Common Stock 65627262 D Exhibit 24.1: Power of Attorney /s/ Lorna A. Knick, by Power of Attorney 2024-08-14 EX-24.1 2 ea021142412ex24-1_citius.htm POWER OF ATTORNEY

Exhibit 24.1

POWER OF ATTORNEY

Know all by these presents, that the undersigned hereby constitutes and appoints each of Jaime Bartushak, Alexander M. Donaldson, and Lorna A. Knick, and each of them acting alone, signing singly, the undersigned’s true and lawful attorney-in-fact to: (1) execute for and on behalf of the undersigned, in the undersigned’s capacity as an officer, director and/or 10% or more stockholder of Citius Oncology, Inc. (the “Company”), Forms ID, 3, 4 and 5, Update Passphrase Acknowledgement (and any amendments thereto) in accordance with Section 16(a) of the Securities Exchange Act of 1934, as amended (the “1934 Act”) and Schedules 13D and/or Schedules 13G (and any amendments thereto) in accordance with the 1934 Act, and the rules promulgated thereunder; (2) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Forms ID, 3, 4 and 5, Update Passphrase Acknowledgement and Schedules 13D and/or Schedules 13G (and any amendments thereto) and to file timely such form with the United States Securities and Exchange Commission and any stock exchange or similar authority; and (3) take any other action of any type whatsoever in connection with the foregoing which in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact’s discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact’s substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned’s responsibilities to comply with Section 16 of the 1934 Act.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms ID, 3, 4 and 5 and Schedules 13D and/or Schedules 13G with respect to the undersigned’s holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned, in a signed writing delivered to each of the foregoing attorneys-in-fact.

The undersigned attests and agrees that the use of an electronic signature in any authentication document that includes the undersigned signatory’s typed, conformed signature, and that is filed with or furnished to the Commission by or on behalf of the undersigned signatory, the Company or any of its affiliates, constitutes the legal equivalent of the undersigned signatory’s manual signature for purposes of authenticating the undersigned signatory’s signature to any filing or submission for which it is provided.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 13^th day of August 2024.

	CITIUS PHARMACEUTICALS, INC.

	By:	/s/ Leonard L. Mazur
		Leonard L. Mazur, Chief Executive Officer